MedTrace Logo

Survivin Urine mRNA Assay Risk of Bladder Cancer Study

NCT00315653 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2008-03-14

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the ability of urinary Survivin mRNA measurement to estimate the risk of bladder cancer at the time of cystoscopy in subjects with no prior history of bladder cancer presenting with microscopic or macroscopic hematuria.

Conditions

Sponsors & Collaborators

  • Fujirebio Diagnostics, Inc.

    lead INDUSTRY

Principal Investigators

  • William J Allard, PhD · Fujirebio Diagnostics, Inc.

  • Jose G Moreno, MD · Tri County Urologic Associates, PC

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00315653 on ClinicalTrials.gov